NL-OMON25535招募中不适用
ongitudinal analysis of lung cancer-specific immunity in stage III and IV non-small cell lung cancer patients.
Stichting Het Nederlands Kanker Instituut - Antoni van Leeuwenhoek ZiekenhuisAmsterdam, The Netherlands0 个研究点目标入组 50 人开始时间: 待定最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 50
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Histologically or cytologically proven irresectable stage III or IV non-small cell lung cancer;
- •2. Age above 18 years;
排除标准
- •1. Severe anemia (Hb < 6.0 mmol/L);
- •2. Any bleeding disorder or anti-coagulation therapy, that cannot be discontinued or corrected, that significantly increases the risk of a bleeding due to the biopsy.
研究者
相似试验
尚未招募
不适用
ongitudinal analysis of lung cancer-specific immunity in stage III and IV non-small cell lung cancer patients10038666non-small cell lung cancerNL-OMON37300Antoni van Leeuwenhoek Ziekenhuis50
已完成
不适用
Immune Response in Lung CancerLung CancerNCT01955343Lithuanian University of Health Sciences100
已完成
不适用
ongitudinal analysis of tumor-specific T-cel immunity in irresectable stage IIIc and stage IV melanoma patientsskin cancermelanoma10040900NL-OMON36481eids Universitair Medisch Centrum50
尚未招募
不适用
The Clinical Characteristics and Efficacy of Immunotherapy in First-line PD-L1-negative Advanced NSCLC PatientsNSCLCNCT06496009Shanghai Pulmonary Hospital, Shanghai, China845
已完成
不适用
Mechanisms of Immunosurveillance for Lung CancerLung CancerNCT01710319Washington University School of Medicine119